国际医药卫生导报2013，Vol.19Issue(6)：838-840,3.DOI:10.3760/cma.j.issn.1007-1245.2013.06.039
哌拉西林舒巴坦钠与莫西沙星在社区获得性肺炎中的疗效差异
Differences in efficacy of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia
摘要
Abstract
Objective To investigate the differences of piperacillin sulbactam sodium and moxifloxacin in community-acquired pneumonia (CAP).Methods A analysis of 140 cases of CAP patients,were randomly divided into two groups,of which 70 cases piperacillin sulbactam sodium; remaining 70 cases moxifloxacin comparative clinical efficacy.Results The moxifloxacin group therapy effective rate of 88.57％ greater than 68.57％ of the piperacillin,the differences were statistically significant(P＜0.05).Conclusions Moxifloxacin in the treatment of CAP more effective than piperacillin sulbactam sodium,and the appropriate cost worth in clinical practice,patients Adaptation and contraindications.关键词
哌拉西林舒巴坦钠/莫西沙星/社区获得性肺炎Key words
piperacillin sulbactam sodium/moxifloxacin/CAP引用本文复制引用
林恒,谢成姬,招伟英..哌拉西林舒巴坦钠与莫西沙星在社区获得性肺炎中的疗效差异[J].国际医药卫生导报,2013,19(6):838-840,3.
